Apr 27 2022 Positive opinion for Amryt’s Filsuvez
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Amryt Pharma’s Filsuvez, a gel treatment for partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa in patients 6 months and older.
The European Commission and the UK’s Medicines and Healthcare Products Regulatory Agency (MHRP) are expected to make decisions on market authorisation by early July. If granted, this will be the first approved treatment for EB.
This is welcome news for dystrophic and junctional EB patients in Europe. Read the update from Amryt Pharma.